Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Myeloid s cell therapy harnesses the innate capabilities of myeloid lineage cells to fight cancer
Scientific founders include world-renowned cell therapy & cancer experts Ronald Vale, Ph.D. and Siddhartha Mukherjee, M.D., D.Phil.
Co-Founded by Thomas Cahill, M.D., Ph.D., with financing led by Newpath Partners and participation from leading biotech investors
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells for treating cancers, launched today with over $50 million in financing to initiate multiple clinical trials in 2021. The Company combines advanced gene and cell engineering capabilities with substantial biologics knowledge to elucidate and redirect the power of myeloid cells to treat cancers, particularly solid tumors and those that are poorly served by exi